報價延遲最少15分鐘:2024/05/18 13:09 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.94 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-9.81/-20.59
|
|
企業價值
31.49M
|
| 資產負債 |
|
每股賬面淨值
11.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
107.00K
|
|
每股收益
0.16
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/18 13:09 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, aninvestigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). |